Skip to NavigationSkip to content

Epiomic™ Epidemiology Forecast Report on Gallbladder Cancer in 18 Major Markets - ref #BS000019

Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Gallbladder Cancer in 18 Major Markets

Gallbladder Cancer (GBC) primarily occurs in the gallbladder itself, but also includes the extrahepatic bile duct, Ampulla of Vater and other non-specified biliary duct tumours. It is currently the most common malignant tumour of the biliary tract worldwide, with a very low survival rate. There are currently no known causes for GBC at this point in time.

This report provides the current incidence population for GBC across 18 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, Canada, Australia, India, Mexico, Turkey, South Africa, Saudi Arabia, Argentina, Russia and China) split by gender and 5-year age cohort. Along with the current incidence, the report provides an overview of the stages, locations and histopathology of GBC tumours. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of GBC have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for GBC include:

  • Obesity
  • Chronic cholecystitis
  • Choleithiasis
  • Gallstones
  • Diabetes

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global GBC’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of GBC and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on GBC’s prevalent population.
  • Examination of the incidence of the different causative gene mutations for GBC.
  • Identify sub-populations within GBC which require treatment.
  • Gain an understanding of the specific markets that have the largest number of GBC patients.

Publisher: Black Swan
Date of publication: October 2015

Price: £ 3,950.00

You need to agree to the Terms and Conditions before placing your order

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches